Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies December 8, 2025 6:00 PM EST

Company Participants

Jason Okazaki - CEO, President & Director Anuj Gaggar - Chief Medical Officer William Delaney - Chief Scientific Officer

Conference Call Participants

Salim Syed - Mizuho Securities USA LLC, Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Georgia Bank - Jefferies LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good evening, and welcome to the Assembly Bio conference call. [Operator Instructions] Please be advised that today’s conference is being recorded and will be available for replay on the Assembly Bio website.

I will now turn the call over to Jason Okazaki, President and CEO of Assembly Bio. Jason, you may begin.

Jason Okazaki CEO, President & Director

Thanks, Carmen, and thank you all for taking the time to join us this afternoon. I’m joined by Dr. Anuj Gaggar, our Chief Medical Officer on this call. Before we get started, I would just like to quickly remind everyone we will be making forward-looking statements, so please refer to our SEC filings for a full list of disclosures.

Today, we’re excited to be able to share what we believe are truly impressive results from our Phase Ib clinical studies of our long-acting helicase-primase inhibitor candidates, ABI-1179 and ABI-5366 in participants with recurrent genital herpes. This is an important moment for the company and individuals living with this disease as both candidates met or exceeded all key objectives of the study. With this data, we believe we now have a path to a potentially best-in-class therapy across key parameters, including dosing interval and improved efficacy versus approved agents.

In a moment, we will dig into the data, but first, I want to provide

Recommended For You